Philippines pharma market to touch US$8bn by 2020

Published: 7-Jul-2014
Media

GlobalData report currently values the market at $4.3m


The value of the Philippines pharmaceutical market is set to increase to US$8bn by 2020, at a compounded annual growth rate of 9.4%, according to research from GlobalData, a research and consulting firm.

Currently, the market is valued at $4.3m. According to the company’s latest report, the Philippines has the third largest pharma market among the countries in the Association of Southeast Asian Nations, after Indonesia and Thailand.

 

'Although an increasing disease burden, coupled with prevailing high pharmaceutical prices, are providing the necessary investment incentives for the healthcare market in the Philippines, limited access to healthcare facilities and governmental cuts could yet impede further growth in the future,' said Joshua Owide, Global Data’s Director of healthcare industry dynamics.

What is even more pertinent is that the public health insurance provider, Philippine Health Insurance Corporation, does not cover the country’s entire population, which means a majority of citizens are unable to afford medicines.

 

Also, high spending to overcome basic economic concerns, such as poverty, dependence on imports and high external debt, have left the Philippines government with less funds to finance the development of healthcare infrastructure, according to Global Data.

  • Companies:
  • GlobalData
See more

You may also like

Media

Eli Lilly’s acquisition of Loxo Oncology will result in quick return of investment

Read more
Eli Lilly’s acquisition of Loxo Oncology marks the second multibillion-dollar deal in 2019 following the recent BMS and Celgene merger

Trending Articles

  1. Johnson Matthey buys Davy Process Technology Johnson Matthey has purchased developer of chemical process technologies, Davy Process Technology (DPT), from Yukos International UK for
  2. GEA Pharma & Healthcare share company updates at CPHI Barcelona Jim Holman, Technology Management Senior Director at GEA Pharma & Healthcare, discusses the company's recent endeavours to enhance the sustainability of their manufacturing procedures, the development of their novel tablet press range and the digital Canary system
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Automated pharmaceuticals Jonathan Wilkins, Marketing Director of obsolete industrial automation parts supplier, EU Automation, explains how technological advances in automation and robotics are benefiting the pharmaceutical industry of today
  4. The evolution of the pharma industry: From reactive to disruptive Globally, the pharma industry has witnessed waves of changes during the last century; we have evolved, writes Ajit Kanetkar, Head, Process Technology, ACG, from maintaining a conservative outlook and being solely reactive to disease and healthcare issues to having a radical and disruptive approach
  5. The top five biopharma manufacturing trends in 2021 Amélie Boulais and Priyanka Gupta of Sartorius discuss the emerging trends that will change how biopharmaceuticals are made

Upcoming event

Cleanroom Conference UK

22–23 May 2024 | Exhibition | Birmingham, UK See all

You may also like

Media

Eli Lilly’s acquisition of Loxo Oncology will result in quick return of investment

Eli Lilly’s acquisition of Loxo Oncology marks the second multibillion-dollar deal in 2019 following the recent BMS and Celgene merger
Media

BMS' acquisition of Celgene could position the company amongst top five most profitable pharma giants

Following the Bristol-Myers Squibb (BMS) announcement on 3 January 2019 that it will acquire Celgene in a cash and stock deal with an equity value of approximately $74 billion, Edit Kovalcsik, Managing Pharma Analyst at GlobalData, offers her view on this significant merger
Media

Drug pricing and reimbursement concerns will remain the leading impediment to industry growth in 2019

In 2019, drug pricing pressure from regulators, patients, politicians and payers will remain and aggressive negotiation tactics to drive down drug prices are expected, says GlobalData, a leading data and analytics company
Media

R&D returns fall to lowest level in 9 years, says Deloitte and GlobalData

Projected returns on investment in research and development (R&D) for the top 12 biopharmaceutical companies have fallen to 1.9%, according to a study by Deloitte’s Centre for Health Solutions leveraging revenue forecasts and industry benchmarks generated by GlobalData
Media

Drug development in neuroimmunology to witness strong growth in the 8MM

Drug development in neuroimmunology is expected to witness strong growth in the eight major markets (US, France, Germany, Italy, Spain, UK, Japan and China), primarily driven by deeper understanding of the underlying pathology of the various diseases, advancements in neurogenetics, and most importantly the potential of the field to develop drugs that offer targeted therapy mechanisms
Media

Immuno-oncology drug development and personalised medicine will continue to reshape the pharma industry in 2019

Immuno-oncology (IO) drug development will remain at the forefront of the pharmaceutical industry in 2019, says GlobalData, a leading data and analytics company
Media

Big Data and AI to transform healthcare by driving innovation, growing revenues and increasing operational efficiencies

Healthtech will rise to prominence in 2019 as Big Data and Artificial Intelligence (AI) become a transformational force in healthcare, says GlobalData, a leading data and analytics company
Subscribe now